Company profile
RenovoRx, Inc.
NASDAQ:RNXTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Gemcitabine | approved | — | 2 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02237157 | phase1 | completed | 2015-03-01 | 2016-09-01 | RenovoRx | A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer |
| NCT03257033 | phase3 | recruiting | 2018-03-12 | 2027-06-01 | RenovoRx | Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC |
FDA applications (0)
No records yet.